U.S. markets closed
  • S&P Futures

    3,844.25
    +35.00 (+0.92%)
     
  • Dow Futures

    31,151.00
    +239.00 (+0.77%)
     
  • Nasdaq Futures

    13,077.25
    +166.25 (+1.29%)
     
  • Russell 2000 Futures

    2,234.90
    +35.70 (+1.62%)
     
  • Crude Oil

    62.56
    +1.06 (+1.72%)
     
  • Gold

    1,748.80
    +20.00 (+1.16%)
     
  • Silver

    26.94
    +0.50 (+1.89%)
     
  • EUR/USD

    1.2088
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3988
    +0.0066 (+0.47%)
     
  • USD/JPY

    106.5720
    +0.0700 (+0.07%)
     
  • BTC-USD

    46,481.41
    +873.27 (+1.91%)
     
  • CMC Crypto 200

    929.06
    -4.08 (-0.44%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,560.41
    +594.40 (+2.05%)
     

PTC Therapeutics (PTCT) Reports Q2 Loss, Lags Revenue Estimates

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

PTC Therapeutics (PTCT) came out with a quarterly loss of $2.65 per share versus the Zacks Consensus Estimate of a loss of $1.29. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -105.43%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.16 per share when it actually produced a loss of $1.80, delivering a surprise of -55.17%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

PTC Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $75.24 million for the quarter ended June 2020, missing the Zacks Consensus Estimate by 5.24%. This compares to year-ago revenues of $85.52 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

PTC Therapeutics shares have added about 1% since the beginning of the year versus the S&P 500's gain of 2.3%.

What's Next for PTC Therapeutics?

While PTC Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for PTC Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.68 on $93.30 million in revenues for the coming quarter and -$5.16 on $346.15 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 49% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PTC Therapeutics, Inc. (PTCT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research